596. AAV Gene Delivery of the Anti-Tau Antibody PHF1 Reduces Brain Tau Pathology in P301L MiceAnti-tau immunotherapy has been proposed as a promising therapy for various tauopathies including Alzheimer's disease (AD), frontotemporal dementia (FTD) and progressive supranuclear palsy (PSP). However...
In this study, we assessed the potential of four anti-tau sdAbs as gene therapy by expressing them transgenically in tauopathy flies. Furthermore, by taking advantage of the ease of genetic manipulation in the flies, we explored their efficacy not only in all neurons but also in different ...
Other new technologies such as the brain shuttle modification or PEST fusion can enhance the penetration of antibody-based drugs into the central nervous system and improve clinical outcomes; additionally, antibodies recognizing Toll-like receptor 2 and tau oligomers are potential therapeutic tools [147...
Based on the present evidences, we propose that any causative-agent targeting immunotherapy for brain disorders, whether it uses active or passive strategies, or whether the causative agent is Aβ, tau, α-synuclein, or other factors, can result in neuronal damage, as long as the antibody with...
Oligomeric forms of amyloid-β (Aβ) and tau are increasing being recognized as key toxins in the pathogenesis of Alzheimer’s disease (AD). We developed a novel monoclonal antibody (mAb), GW-23B7, that recognizes β-sheet secondary structure on patholog
Background: Cancer is a disease which affects the elderly, just like Alzheimer's Disease (AD) which is also a common disease affecting older people. Most of the symptoms are related with both these diseases, therefore there may be therapeutic link between anticancer drugs and AD. Little is kn...
Misfolding and aggregation of tau protein are closely associated with the onset and progression of Alzheimer's Disease (AD). By interrogating IgG+memory B cells from asymptomatic donors with tau peptides, we have identified two somatically mutated VH5–51/VL4–1 antibodies. One of these, CBTAU...
Tau antibody chimerization alters its charge and binding, thereby reducing its cellular uptake and efficacy. EBioMedicine. 2019;42:157–73. doi:10.1016/j.ebiom.2019.03.033. (Open in a new window)PubMed (Open in a new window)Web of Science ®(Open in a new window)Google Scholar ...
Vaccination has so far been unsuccessful in the generation of effective PrP-specific antibody responses in mice because of tolerance to PrPC. Furthermore, therapy with CpG-containing oligodeoxynucleotides, using a multi-dose regimen, causes unwanted toxic side-effects. However, another option for treat...
We investigated the therapeutic efficacy of two different antibodies that specifically target acetylated lysine 174 on tau (ac-tauK174). We treated PS19 mice, which harbor the P301S tauopathy mutation that causes FTLD, with anti-ac-tauK174 and measured effects on tau pathology, neurodegeneration,...